Fig. 3: Overall survival in the intensive and non-intensive studies. | Leukemia

Fig. 3: Overall survival in the intensive and non-intensive studies.

From: Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial

Fig. 3

A Overall survival in patients treated with glasdegib or placebo plus cytarabine and daunorubicin. B Overall survival in patients treated with glasdegib or placebo plus azacitidine. aGlasdegib vs. placebo. CI confidence interval, HR hazard ratio, OS overall survival.

Back to article page